AMADIS
1.5.2022 07:02:07 CEST | Business Wire | Press release
Amadis , a leading payment software and consulting provider, today announced a partnership agreement with Softpay.io to provide its Universal EMV Level 2 Framework & pre-certified Kernels for integration into Softpay’s new Tap-to-Pay service. Softpay’s revolutionary Tap-to-Pay service can be downloaded into any Android device and turn into a full payment card acceptance terminal. Softpay’s solution provides merchants with greater flexibility and future proofing capabilities, while lowering costs and creating new revenue opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220430005009/en/
The Amadis solution is a component of its Amadis One software framework composed of an EMV L2 Framework and ecosystem supporting any EMV Contactless Kernel. It enables Softpay’s service to seamlessly accept EMV payments on Android-based COTS devices with NFC capabilities, reduces the time for Softpay to roll out new products and provide payment acceptance of any payment schemes, on its new mobile payments platform. Amadis One software framework is the first solution to enable nexo (ISO 202022) standards on Tap-to-Pay platforms.
“Softpay’s solution helps us to transform the shopping experience, enabling our store associates to check out customers anywhere in-store, or at curbside,” said Thomas Grane, CIO, at Matas. “The solution drives new sales opportunities, and enables a more efficient, personalized customer experience.”
Softpay’s Tap-to-Pay is impacting several industries, including retailers and QSRs, who can operate more efficiently. Staff can accept payments, while multi-tasking anywhere in-store, or at curbside pickup locations. Transit companies can drive new points of sale by instantly offering and processing new and upgraded tickets, while passengers are on board trains and buses.
“Softpay’s Tap-to-Pay service provides innovative new experiences to retail, transportation and the QSR industries, and our Amadis One software framework helps them bring products to market faster,” said Emmanuel Haydont, CEO and co-founder, Amadis. “Amadis One commoditizes complex payment processes, freeing up resources for merchants to innovate, accelerating time to market and reducing costs, while enhancing the customer experience.”
“By integrating Amadis One with our Tap-to-Pay solution, we enable merchants to revolutionize the customer experience, while lowering their costs and providing greater flexibility,” said Craig Jacoby, CEO, Softpay.io. “By enabling tap-to-pay transactions on smartphones, merchant fees for card present transactions are lowered, new customer points of interactions (POIs) are generated, creating innovative new ways to interact with customers, while processing transactions.”
About Softpay.io
Softpay was founded in 2019 to take advantage of the new Visa and Mastercard specifications for payment terminals which enabled Softpay to develop a mobile application that allows merchants to turn a regular phone into a contactless payment terminal with PIN. Softpay has grown into a company with more than 30 employees and is headquartered in Copenhagen, Denmark. Softpay has received more than €9 mill in funding and the ambition is to be one of the leading global providers of tap-to-phone solutions. Leading European payment companies have decided to partner with Softpay and Softpay is now focusing on North America as well.
About Amadis
Amadis is a leader in payment card acceptance software technology, with its software running on more than 50 million devices worldwide. The company provides state-of-the-art software products, frameworks and solutions for global merchants, payment terminal manufacturers and payment processors. Amadis provides merchants with the industry’s broadest range of EMV card processing options using custom or commercially available technology, independent of hardware, operating system or geography. The company brings an elite, experienced software team to the industry and enables solutions for international acceptors in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220430005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom